Clinical Trial Update: A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase II study evaluating zanubrutinib with lenalidomide and R-CHOP as first-line therapy for diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• R-CHOP
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 2 | Status: UNKNOWN